@Steloco1 @look2theblue the guy dragged this out of the grave after that crazy CRL. It's been a crazy decade. he ain't gonna take an insulting offer.
If they don't cave in and give a real offer, he should go outside the US to $NVO or $CSPCY
@WhereistheSEC @Amb8675309 oral penem will get to market regardless. plenty of options. BO with big pharma is just the fastest.
also consider outside the G7. $CSPCY is one of the largest manufacturer of antibiotics. AMR is a bigger problem outside the G7 and given the last several decades, they will have more money.
@look2theblue oral penem will bring in billions per year. plenty of options now and in the future. who wouldn't fund this?
Also, it doesn't have to be $PFE or $AMGN. $MRK is the 2nd largest in antibiotics with a focus on multi drug resistant infections. They can buy just to prevent oral penem. there's also novo (eu based). Of course we always forget that the vast majority of the people and drugs are outside the US. $CSPCY being one of the largest manufacturer of antibiotics.
Still, $PFE has the most to gain. They're the biggest in antibiotics and they need to eat something soon after their last ER. They have a 15% stake in the timely and efficient introduction of the drug regardless of who buys and they can market faster than anyone else, saving lives and their reputation. I don't do "jim plays pickle ball with bob" type of DD but $PFE is the easiest, well traveled road.
$YI Here's an interesting interview with Steve Alain Lawrence from CNBC, CIO at Balfour Capital. He has some interesting things to say about value in the pharma industry in China, starting at 1:16.
https://www.youtube.com/watch?v=OJwfEkDDk7c
Of note: YI has been running with $CSPCY as of late.
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Valuation
Trading at 1.0× earnings vs its 2.1× historical median P/E.
Fair value ≈ $7.35 · price $3.58 today
Undervalued · 51% below
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
